GEN Exclusives

More »

GEN News Highlights

More »
Mar 19, 2008

Alkermes Prompted to Restructure with Eli Lilly’s Decision to Drop Inhaled Insulin Development

  • Alkermes is cutting 150 jobs, or 18% of its workforce, in light of Eli Lilly’s decision to ax development of the firms’ inhaled insulin product, AIR® Insulin. The company is also closing its commercial manufacturing facility in Chelsea, MA. Alkermes will bear related charges of between $20 and $25 million.

    On March 7, Eli Lilly reported that it would no longer develop AIR Insulin, which was already in Phase III trials. Eli Lilly said that while there were no safety issues with the product, the firm did not believe that it had sufficient commercial potential. In fact, last year Pfizer decided to abandon its inhaled insulin treatment, Exubera, after the product failed to meet market expectations.

    Alkermes expects to take a restructuring charge in the fourth quarter of fiscal 2008 in the range of $5 to $10 million associated with workforce reduction and facility expenses. In addition, the company anticipates an impairment charge of up to $15 million in the fourth quarter of fiscal 2008 related to fixed assets at the Chelsea facility.
    Alkermes says that it will see cost savings from this move in the range of $15 million to $20 million in fiscal 2009.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »